Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
09:09pm, Wednesday, 06'th Aug 2025
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relatio
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Wednesday, 06'th Aug 2025
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.52 per share a year ago.
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 06'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:07am, Wednesday, 30'th Jul 2025
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
11:06am, Thursday, 17'th Jul 2025
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:15pm, Thursday, 10'th Jul 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up
12:34pm, Tuesday, 17'th Jun 2025
Biotech stock Mirum Pharmaceuticals has rocketed 236% since its IPO in 2019. Shares are near a buy point after earnings.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:40pm, Tuesday, 10'th Jun 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
12:36pm, Friday, 06'th Jun 2025
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
08:30am, Monday, 19'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #leadership--Mirum Pharmaceuticals Appoints Doug Sheehy, JD as Chief Legal Officer.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 14'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the
Mirum Pharmaceuticals price target raised by $4 at Raymond James, here's why
08:08am, Tuesday, 13'th May 2025
29 May
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Friday, 09'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL
08:30am, Friday, 09'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $mirm #easl2025--Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL.
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
01:16pm, Thursday, 08'th May 2025
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance.
